Tecentriq Indications/Uses

Urothelial carcinoma: Tecentriq as monotherapy is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC): after prior chemotherapy, or who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥ 5%.
Early-stage non-small cell lung cancer: Tecentriq as monotherapy is indicated as adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II to IIIA (7th edition of the UICC/AJCC-staging system) NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells (TC).
Metastatic non-small cell lung cancer: Tecentriq, in combination with Avastin (bevacizumab), paclitaxel and carboplatin, is indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq.
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR or ALK genomic tumor aberrations.
Tecentriq as monotherapy is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have a PD-L1 expression* ≥ 50% tumor cells (TC) or ≥ 10% tumor-infiltrating immune cells (IC) and who do not have EGFR or ALK genomic tumor aberrations.
* apply for any PD-L1 IHC assays.
Tecentriq as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
Small cell lung cancer: Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Triple-negative breast cancer: Tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression of ≥1% on IC, and who have not received prior chemotherapy for metastatic disease.
Hepatocellular carcinoma: Tecentriq, in combination with Avastin (bevacizumab), is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.